Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
about
Low-dose rate brachytherapy for men with localized prostate cancerLow-dose rate brachytherapy for men with localized prostate cancerEndoglin (CD105) as a urinary and serum marker of prostate cancerA first-generation multiplex biomarker analysis of urine for the early detection of prostate cancerThe University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomyOverexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathwayRisk stratification and early oncologic outcomes following robotic prostatectomyPathological outcomes and strategies to achieve optimal cancer control during robotic radical prostatectomy in Asian-Indian menPlasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancerSpatial Genome Organization and Its Emerging Role as a Potential Diagnosis ToolMolecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerSaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerContemporary Management of Prostate CancerHormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerConcurrent chemoradiation for high-risk prostate cancerOptimal management of prostate cancer with lethal biology--state-of-the-art local therapyMultiparametric magnetic resonance imaging for prostate cancer: A review and update for urologistsNeuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failureManagement of low (favourable)-risk prostate cancerHigh-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancerComparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupRationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancerIntense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.Grading of prostatic adenocarcinoma: current state and prognostic implicationsWhat's new in prostate cancer research?Effects of supplemental vitamin D and calcium on normal colon tissue and circulating biomarkers of risk for colorectal neoplasmsAn accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into accountSeminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced diseaseRadical Prostatectomy versus External Beam Radiotherapy for cT1-4N0M0 Prostate Cancer: Comparison of Patient Outcomes Including MortalityProstate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal TherapyEffect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical ProstatectomyTools for predicting patient-reported outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validity.Outcomes and toxicities in patients treated with definitive focal therapy for primary prostate cancer: systematic review.Imaging on nodal staging of prostate cancer.Surgical and postoperative factors affecting length of hospital stay after radical prostatectomy.Prostatourethral-rectal fistula after prostate brachytherapy.Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients.Assessment of histopathological features of needle biopsy in recurrent prostate cancer following salvage high-intensity focused ultrasound.Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results
P2860
Q24235544-38D4BF39-8591-45A8-8576-5E6B0DDDFF44Q24236127-B8064432-7D2F-44A2-97FF-717B2F91398BQ24314256-EAC68E95-768B-4C2B-9CEA-116182F5ABD9Q24569630-0A93852C-9383-408F-A37C-B8766CFFD21DQ24596735-77E1E1B2-E3CC-4BAC-9EFE-DEE64196D1F4Q24620497-B0D185F5-97AC-47B3-B762-36290F12FD2AQ24632732-E01C0C1A-C27F-42C0-9BE1-8E7A74FA98C9Q24635051-4FF54C54-3C03-4735-9CBD-CC68DBE5C8DEQ24657886-2A4F5BA0-C9A6-4009-A598-2D0AFFD32E69Q26738275-24C803E0-5CE7-4680-90C6-3AA21193FD25Q26739708-E3D0EF1A-5F89-42C0-B32F-0A769C0DB20DQ26747782-17984B32-A272-42D7-B1B9-3505FDE4DA0BQ26766638-E969E71F-B0AD-4BBB-A3FE-9792956F9640Q26767456-0FBEA896-C73C-4C09-8C4C-51D52D0BAE75Q26773634-DE35CC89-4CDA-4B78-AAEF-0332DE2A5726Q26798912-77E89FF5-3D88-4E6A-AC70-41F44DD235E5Q26801188-B920661C-E4E7-4659-9B32-79EA01EDD705Q26801576-046F8033-609B-4C32-A739-BD1F4A487DD6Q26859201-BF30C44B-4953-4B5A-8A4F-E4E001A0985CQ26996501-C15E27FF-03FD-475E-96A7-8D96AD240EE4Q26996937-E6D2540D-0455-4A55-B842-CF57BE233AA8Q27011661-68214489-3860-4C29-A18E-D1264ABB3EB8Q27028084-0D2574EB-FDFB-43D9-B306-0CFA3552BD62Q27313709-31E556AA-BED9-4059-89C5-0972A15D497FQ28066111-807E0ED9-6A22-4EC7-A701-3C069BED99DFQ28078502-528F22AF-A4AE-4D68-A59A-43DBE5984DC1Q28083343-8C94C2A6-6654-40F6-81DE-4FF148AE9338Q28484126-E3B24979-0776-4715-9AC0-1243C977AC94Q28534235-E345FBB2-8C3B-4D89-8085-EB906E4ACB27Q28550520-D43AF2B4-7134-4921-AC37-0364B880BC7AQ28550782-F47E63AB-36A5-4A96-8BCE-28AD48F9C6D3Q28554583-BBE541E9-6C12-4901-85B2-2B34AAEC641BQ30234092-BF3FF743-6309-441A-B932-782CFC497014Q30241856-BBCDA385-320F-428A-86A3-7108877F68C8Q30244033-7E979168-C31A-453A-BFC8-DFCD06E648D3Q30305900-2F2DDC93-AC6B-450C-875F-0958CD747213Q30306333-C3DD5688-3607-493A-B6F7-ACCA9EF44ED4Q30310352-663E84CC-2648-4498-BA0B-800E37E8898CQ30365597-405B18F6-44A4-48BF-B69E-CB69C8A0CAFAQ30382135-579D7624-6A66-4E66-952E-EBB57112E2C5
P2860
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Biochemical outcome after radi ...... lly localized prostate cancer.
@en
Biochemical outcome after radi ...... lly localized prostate cancer.
@nl
type
label
Biochemical outcome after radi ...... lly localized prostate cancer.
@en
Biochemical outcome after radi ...... lly localized prostate cancer.
@nl
prefLabel
Biochemical outcome after radi ...... lly localized prostate cancer.
@en
Biochemical outcome after radi ...... lly localized prostate cancer.
@nl
P2093
P356
P1476
Biochemical outcome after radi ...... ally localized prostate cancer
@en
P2093
A A Renshaw
A V D'Amico
J E Tomaszewski
R Whittington
S B Malkowicz
P304
P356
10.1001/JAMA.280.11.969
P407
P577
1998-09-01T00:00:00Z